- Home
- WDI vs ESPR Comparison
WDI vs ESPR Comparison
Compare WDI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WDI | ESPR |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.9M | 660.1M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | WDI | ESPR |
|---|---|---|
| Price | $14.34 | $4.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.86 |
| AVG Volume (30 Days) | 192.6K | ★ 7.4M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 11.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | ★ $303,802,000.00 |
| Revenue This Year | N/A | $18.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.82 | ★ N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $12.16 | $0.69 |
| 52 Week High | $14.69 | $4.02 |
Technical Indicators
Market Signals| Indicator | WDI | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 46.14 | 75.37 |
| Support Level | $14.05 | $2.66 |
| Resistance Level | $14.51 | $3.26 |
| Average True Range (ATR) | 0.16 | 0.23 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 61.96 | 98.18 |
Price Performance
Historical ComparisonAbout WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.